Nx GEN SEQUENCING GLAUCOMA Test
Components
- ACVR1
- ASB10
- BEST1
- CANT1
- COL18A1
- CYP1B1
- FOXC1
- LMX1B
- LOXL1
- LTBP2
- MYOC
- NTF4
- OPTN
- PAX6
- PITX2
- PITX3
- SBF2
- WDR36
Price
5730.0 AED
Sample Condition
Submit 10 mL (5 mL min.) whole blood from 2 Lavender Top (EDTA) tubes. Ship refrigerated. DO NOT FREEZE.
Duly filled Whole Exome Sequencing Consent Form (Form 37) is mandatory.
Report Delivery
Sample Daily by 9 am; Report 45 Working days
Method
NGS, Sanger sequencing
Test Type
Glaucoma
Doctor
Ophthalmologist
Test Department
MOLECULAR DIAGNOSTICS
Pre Test Information
Duly filled Whole Exome Sequencing Consent Form (Form 37) is mandatory.
Test Details
Glaucoma is a group of eye diseases that damage the optic nerve, which is responsible for transmitting visual information from the eye to the brain. It is the leading cause of irreversible blindness worldwide. Early detection and treatment can help prevent vision loss, but currently available diagnostic tests have limitations. Next-generation sequencing (NGS) is a powerful tool that can analyze multiple genes simultaneously and detect genetic variations that may contribute to glaucoma. NGS-based glaucoma testing can help identify individuals who are at risk of developing the disease and enable early intervention. NGS-based glaucoma testing can also provide valuable information for personalized treatment plans and genetic counseling. It can help identify the specific genetic mutations that are responsible for glaucoma in an individual, which can guide the selection of appropriate medications and surgical interventions. Overall, NGS-based glaucoma testing has the potential to improve the accuracy of glaucoma diagnosis and management, leading to better outcomes for patients.
Test Name | Nx GEN SEQUENCING GLAUCOMA Test |
---|---|
Components | ACVR1, ASB10, BEST1, CANT1, COL18A1, CYP1B1, FOXC1, LMX1B, LOXL1, LTBP2, MYOC, NTF4, OPTN, PAX6, PITX2, PITX3, SBF2, WDR36 |
Price | 5730.0 AED |
Sample Condition | Submit 10 mL (5 mL min.) whole blood from 2 Lavender Top (EDTA) tubes. Ship refrigerated. DO NOT FREEZE.Duly filled Whole Exome Sequencing Consent Form (Form 37) is mandatory. |
Report Delivery | Sample Daily by 9 am; Report 45 Working days |
Method | NGS, Sanger sequencing |
Test type | Glaucoma |
Doctor | Ophthalmologist |
Test Department: | MOLECULAR DIAGNOSTICS |
Pre Test Information | Duly filled Whole Exome Sequencing Consent Form (Form 37) is mandatory. |
Test Details |
Glaucoma is a group of eye diseases that damage the optic nerve, which is responsible for transmitting visual information from the eye to the brain. It is the leading cause of irreversible blindness worldwide. Early detection and treatment can help prevent vision loss, but currently available diagnostic tests have limitations. Next-generation sequencing (NGS) is a powerful tool that can analyze multiple genes simultaneously and detect genetic variations that may contribute to glaucoma. NGS-based glaucoma testing can help identify individuals who are at risk of developing the disease and enable early intervention. NGS-based glaucoma testing can also provide valuable information for personalized treatment plans and genetic counseling. It can help identify the specific genetic mutations that are responsible for glaucoma in an individual, which can guide the selection of appropriate medications and surgical interventions. Overall, NGS-based glaucoma testing has the potential to improve the accuracy of glaucoma diagnosis and management, leading to better outcomes for patients. |